Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics granted inducement stock options to purchase 16,500 shares of common stock to two new non-executive employees as of June 30, 2026.
Key figures
- Exercise price
- 40.63
- Shares granted
- 16500
- Employees affected
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.